Millstone Evans Group’s Moderna MRNA Stock Holding History

Millstone Evans Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.09K	Hold	87	–	–	﹤0.01%	653
2026 Q1	$4.42K	Hold	87	–	–	﹤0.01%	669
2025 Q4	$2.57K	Hold	87	–	–	﹤0.01%	729
2025 Q3	$2.25K	Hold	87	–	–	﹤0.01%	732
2025 Q2	$2.4K	Hold	87	–	–	﹤0.01%	661
2025 Q1	$2.47K	Hold	87	–	–	﹤0.01%	681
2024 Q4	$3.62K	Buy	+87	New	+$4.16K	﹤0.01%	602

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Millstone Evans Group's MRNA Position: Q2 2026 in Review

Millstone Evans Group held its Moderna (MRNA) position steady in Q2 2026 at 87 shares worth $6.09K. The position accounts for ﹤0.01% of the portfolio, ranked #653.

Millstone Evans Group first reported a position in MRNA in Q4 2024 and has held it in 7 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Millstone Evans Group held 87 shares of Moderna worth $6.09K as of Q2 2026.
Millstone Evans Group left its Moderna share count unchanged in Q2 2026.
Moderna made up ﹤0.01% of Millstone Evans Group's portfolio in Q2 2026, its #653 holding.
Millstone Evans Group first reported a position in Moderna in Q4 2024 and has held it in 7 quarters since.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.